Prelude Therapeutics Inc represents values of innovation, collaboration, and dedication to improving patients' lives. With a strong corporate philosophy focused on developing novel small molecule therapies for cancer treatment, Prelude Therapeutics Inc strives to bring transformative medicines to individuals in need. Their commitment to scientific excellence, cutting-edge research, and strategic partnerships enables them to address unmet medical needs and advance the field of precision oncology. By leveraging their expertise in targeted protein degradation, Prelude Therapeutics Inc aims to make a significant impact on the lives of patients battling cancer.

Prelude Therapeutics Inc is primarily present in the United States.

Prelude Therapeutics Inc, a leading biopharmaceutical company, has achieved significant milestones in its remarkable journey. The company has successfully advanced its innovative pipeline, focusing on the discovery and development of small molecule therapies. Prelude Therapeutics Inc has achieved major breakthroughs in the field of oncology and precision medicine, showcasing promising results in preclinical and clinical studies. By leveraging its cutting-edge research and development capabilities, Prelude Therapeutics Inc aims to address unmet medical needs for patients with cancer and other serious diseases. With its strong commitment to transformative treatments, Prelude Therapeutics Inc continues to make strides in the field of therapeutic advancements.

Prelude Therapeutics Inc is a biopharmaceutical company focused on developing precision medicines. Established in [year], Prelude Therapeutics has a rich history in drug discovery and has become a leader in targeting novel mechanisms for cancer treatment. The company leverages its expertise in small molecule drug design along with cutting-edge research in cancer biology to develop therapies that target specific genetic alterations driving cancer growth. Prelude Therapeutics strives to improve patients' lives by advancing precision medicine approaches through innovative drug development.

The main competitors of Prelude Therapeutics Inc in the market are large biotechnology companies such as Amgen Inc, Gilead Sciences Inc, and Vertex Pharmaceuticals Inc.

Prelude Therapeutics Inc is primarily active in the field of biotechnology and pharmaceuticals.

The business model of Prelude Therapeutics Inc is focused on developing small molecule therapies to target cancer and other serious diseases. They employ a precision medicine approach, leveraging their expertise in molecular biology, cancer biology, and medicinal chemistry to identify and optimize drug candidates. Prelude Therapeutics aims to address unmet medical needs by creating innovative treatments that can target specific genetic mutations and signaling pathways in order to inhibit tumor growth and enhance patient outcomes. Through intensive research and clinical development, the company strives to bring potential life-changing therapies to patients in need.

Prelude Therapeutics의 P/E 비율은 -0.73입니다.

Prelude Therapeutics의 P/S 비율은 0입니다.

Prelude Therapeutics에 대한 AlleAktien 품질 점수는 2/10입니다.

Prelude Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

예상되는 Prelude Therapeutics 이익은 -102.78 백만 USD입니다.

Prelude Therapeutics is a biotechnology company specializing in the discovery and development of drugs to treat cancer and inflammatory diseases. The company has a team of experts in drug research and is headquartered in Wilmington, North Carolina. Its business model is focused on discovering and developing novel drugs tailored to the specific needs of cancer and inflammation patients. The company uses an innovative platform technology to identify and validate potential new drugs and therapies. Prelude Therapeutics aims to develop groundbreaking drugs targeting new therapeutic approaches to effectively treat cancer and inflammatory diseases. It is divided into several business areas, including cancer research and inflammation research, and offers contract manufacturing services. The company is currently in the early stages of drug development and does not have any approved products on the market. However, it has made promising progress in the preclinical development of its drug candidates, including PRMT5 inhibitors for the treatment of various types of cancer. Its strategy is to discover and develop novel drugs that are more effective and specific in treating cancer and inflammatory diseases. Prelude Therapeutics has the potential to become a leading player in drug development for cancer and inflammatory diseases, addressing many of today's medical challenges.

Prelude Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Prelude Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Prelude Therapeutics의 ISIN은 US74065P1012입니다.

Prelude Therapeutics의 티커는 PRLD입니다.

지난 12개월 동안 Prelude Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Prelude Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Prelude Therapeutics의 현재 배당 수익률은 입니다.

Prelude Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Prelude Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Prelude Therapeutics은 '건강' 섹터에 속합니다.

Prelude Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Prelude Therapeutics는 0 USD를 배당금으로 지급했습니다.

Prelude Therapeutics의 배당금은 USD에 지급됩니다.